Abstract
Previous studies have shown that the adenovirus E1A oncoprotein can bind to and inactivate the retinoblastoma tumor suppressor protein (pRb) and the transcriptional coactivators CBP/p300. In this study, wild-type E1A12S or two deletion mutants (delN, which binds pRb but not CBP/p300; delCR2, which binds to CBP/p300 but not pRb) were linked to the lens-specific αA-crystallin promoter, and used to generate transgenic mice. Lens fiber cells expressing E1A12S or delCR2, both of which bind to CBP/p300, failed to upregulate β-crystallin and γ-crystallin expression. In contrast, lens fiber cells expressing delN showed significant expression of β- and γ-crystallins. Lens fiber cells expressing delN showed cell cycle entry, marked apoptosis, and evidence for p53 activation, while cells expressing either 12S or delCR2 showed limited apoptosis and no evidence for upregulation of the p53-inducible gene p21. Our results suggest that the transcriptional coactivators CBP and/or p300 are required for the dramatic increases in crystallin expression that accompany terminal differentiation in the lens, and also for activation of p53 in response to inactivation of pRb in the lens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bagchi S, Raychaudhuri P, Nevins JR . 1990 Cell 62: 659–669
Bannister AJ, Kouzarides T . 1995 EMBO J. 14: 4758–4762
Barbeau D, Charbonneau R, Whalen SG, Bayley ST, Branton PE . 1994 Oncogene 9: 359–373
Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH . 1993 Nature 365: 855–859
Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, Livingston DM . 1994 Genes Dev. 8: 869–884
Eckner R, Yao TP, Oldread E, Livingston DM . 1996 Genes Dev. 10: 2478–2490
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B . 1993 Cell 75: 817–825
Fromm L, Shawlot W, Gunning K, Butel JS, Overbeek PA . 1994 Mol. Cell. Biol. 14: 6743–6754
Fromm L, Overbeek PA . 1996 Oncogene 12: 69–75
Gu W, Roeder RG . 1997 Cell 90: 595–606
Jones N . 1995 Curr. Top. Microbiol. Immunol. 199: 59–80
Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM . 1997 Nature 387: 823–827
McAvoy JW . 1978 J. Embryol. Exp. Morphol. 44: 149–165
Moran E . 1993 Curr. Opin. Genet. Dev. 3: 63–70
Morgenbesser SD, Williams BO, Jacks T, DePinho RA . 1994 Nature 371: 72–74
Mymryk JS, Lee RW, Bayley ST . 1992 Mol. Cell. Biol. 3: 1107–1115
Nishiguchi S, Wood H, Kondoh H, Lovell-Badge R, Episkopou V . 1998 Genes Dev. 12: 776–781
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y . 1996 Cell 87: 953–959
Piatigorsky J . 1981 Differentiation 19: 134–153
Reynaud EG, Pelpel K, Guillier M, Leibovitch MP, Leibovitch SA . 1999 Mol. Cell. Biol. 19: 7621–7629
Ring BZ, Cordes SP, Overbeek PA, Barsh GS . 2000 Development 127: 307–317
Robinson ML, Overbeek PA, Verran DJ, Grizzle WE, Stockard CR, Friesel R, Maciag T, Thompson JA . 1995 Development 121: 505–514
Robinson ML, Overbeek PA . 1996 Invest. Ophthalmol. Vis. Sci. 37: 2276–2284
Smith ML, Kontny HU, Bortnick R, Fornace Jr AJ . 1997 Exp. Cell Res. 230: 61–68
Somasundaram K, El-Deiry WS . 1997 Oncogene 14: 1047–1057
Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT et al . 1991 Proc. Natl. Acad. Sci. USA 88: 2065–2069
Treton JA, Jacquemin E, Courtois Y, Jeanny JC . 1991 Differentiation 47: 143–147
Trouche D, Kouzarides T . 1996 Proc. Natl. Acad. Sci. USA 93: 1439–1442
Wigle JT, Chowdhury K, Gruss P, Oliver G . 1999 Nat. Genet. 21: 318–322
Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM, Eckner R . 1998 Cell 93: 361–372
Zhang P, Wong C, DePinho RA, Harper JW, Elledge SJ . 1998 Genes Dev. 12: 3162–3167
Acknowledgements
We thank Greg Barsh, Brian Ring and Michael Schneider for helpful comments on the manuscript; Gaby Schuster for generating the transgenic mice; Long Vien, Barbara Harris and Rachel Charbonneau for excellent technical assistance. This research was supported by NRSA fellowship EY-06708 (JD Ash), NIH grants EY-10448, EY-10803, EY-11348 (PA Overbeek); and a grant from the National Cancer Institute of Canada (P Branton).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, Q., Ash, J., Branton, P. et al. Inhibition of crystallin expression and induction of apoptosis by lens-specific E1A expression in transgenic mice. Oncogene 21, 1028–1037 (2002). https://doi.org/10.1038/sj.onc.1205050
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205050
Keywords
This article is cited by
-
Reversible inactivation of the transcriptional function of P53 protein by farnesylation
BMC Biotechnology (2006)
-
Lens cell targetting for gene therapy of prevention of posterior capsule opacification
Gene Therapy (2006)
-
Prevention of posterior capsule opacification by the induction of therapeutic apoptosis of residual lens cells
Gene Therapy (2006)